Targeting intracerebral inflammation in multiple sclerosis: Is it feasible?

Acta Neuropathologica

Volumn 124, Issue 3, 2012, Pages 395-396

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CUPRIZONE; CYTOKINE; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAQUINIMOD; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CELL FUNCTION; CELL MIGRATION; CELLULAR IMMUNITY; DEMYELINATION; DISEASE ACTIVITY; DISEASE CONTROL; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; ENCEPHALITIS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LIPID DEGRADATION; LIPID METABOLISM; LIPOGENESIS; LYMPHOCYTE SUBPOPULATION; MONOCYTE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; NOTE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RELAPSE; TH1 CELL; TH2 CELL;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; CERAMIDES; DEMYELINATING DISEASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS; NF-KAPPA B; OLIGODENDROGLIA; PROPYLENE GLYCOLS; QUINOLONES; SPHINGOSINE;

EID: 84865860872     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-012-1015-3     Document Type: Note

References (11)

1. Brück W, Pförtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, Hanisch UK, Regen T, van Rossum D, Brakelmann L, Hagemeier K, Kuhlmann T, Stadelmann C, John GR, Kramann N, Wegner C (2012) Reduced astrocytic NF-kB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol (Berl) (this issue). doi:10.1007/s00401-012-1009-1
2. Brück W, Wegner C (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306:173-179
3. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366:1000-1009
4. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469-475
5. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis. Brain 132:1175-1189
6. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, Korosec T, Kutzelnigg A, Berger JJ, Bradl M, Bittner RE, Lassmann H (2006) Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65:855-865 (Pubitemid 44371231)
7. Kappos L, Radue EW, O'Connor P, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401
8. Reynolds R, Roncaroli F, Nicholas B, Gveric D, Howell O (2011) The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol (Berl) 122:155-170
9. Sofroniew MV, Vinters HV (2010) Astrocytes; biology and pathology. Acta Neuropathol (Berl) 119:7-35
10. Van Doorn R, Nijland PG, Dekker N, Witte ME, van het Hof B, Kooij G, Reijerkerk A, Dijkstra C, van der Valk P, van Horssen J, de Vires H (2012) Fingolimod attenuates ceramide-induced blood brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol (Berl) (this issue). doi:10.1007/s00401-012-1014-4
11. Wiendl H, Hohlfeld R (2009) Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 72:1008-1015